A new approach Researchers at Yale University are embarking on a groundbreaking clinical trial to assess the effectiveness of psilocybin for treating Obsessive Compulsive Disorder (OCD). The trial aims to offer new insights into psilocybin's potential as a treatment, particularly for patients who have not found relief through traditional medications and therapies. - Trial structure The study is the first of its kind to use a randomized, waitlist-controlled, and blinded approach, along with non-directive psychological support, to explore psilocybin's efficacy for OCD treatment. - Potential impact Psilocybin has shown promise in treating a variety of psychiatric conditions by enhancing neural plasticity and disrupting established patterns of thought and behavior, which could be particularly beneficial for OCD sufferers. - Study design Participants aged 21 to 55 will receive two fixed doses of psilocybin in a controlled setting, with outcomes measured using the Yale-Brown Obsessive-Compulsive Scale to evaluate symptom reduction, safety, and tolerability.